Skip to content

Organon OGN Debt-to-equity

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Amgen logo
AmgenAMGN
6.2×-3.0×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
0.4×+0.1×
Biogen logo
BiogenBIIB
0.4×+0.1×
AbbVie logo
AbbVieABBV
46.6×+38.6×
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
127.9×+119×

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Current ratio+0.3×

Where this comes from

Calculated from Organon’s reported figures.

Based on the most recent quarter.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's debt-to-equity?
Organon (OGN) reported debt-to-equity of 9.5× in Q1 2026.
How has Organon's debt-to-equity changed year-over-year?
Organon's debt-to-equity decreased by 42.6% year-over-year, from 16.5× to 9.5×.
What is the long-term trend for Organon's debt-to-equity?
Over 2 years (2020 to 2025), Organon's debt-to-equity has grown at a 4431.0% compound annual growth rate (CAGR), from 0× to 11.7×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.